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Background: We tested the hypothesis that the Asian cystic fibrosis (CF) phenotype is comparable to the commonest genetic form of CF
found in 50% of the white UK CF population using the UK CF Database, a national disease-specific patient registry.
Methods: 50 Asian CF patients were matched by Centre with 143 white homozygous DF508 patients for gender, age and chronic
Pseudomonas aeruginosa status (a marker of morbidity). The authors compared FEV1 and FVC% predicted, mean height, weight and BMI Z
scores.
Results: FVC% predicted, weight and BMI Z scores were significantly worse in the Asians. Asian male/female FVC% predicted ( p-value,
95% CI) 15.1 ( p=0.001, 24.0, 8.8)/15.2 ( p=0.014, 27.1, 3.3) compared with white controls. Asian females also had significantly
worse FEV1% predicted compared with controls (14.9, p=0.025, 95% CI: 27.8, 2.0). Asians had significantly lower raw Z scores for
weight (males p=0.002, females p=0.013) and BMI (males p=0.002, females p=0.008).
Conclusions: These data suggest that the Asian CF phenotype is as severe as the white controls with the homozygous DF508 phenotype but
is worse in some outcomes, especially in Asian females. Socio-cultural factors and rare CF genotypes may contribute to the severity of CF in
this vulnerable group.
D 2004 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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Cystic fibrosis (CF) is usually thought of as a Caucasian
disease [3,4] although Asians from the Indian subcontinent
constitute 1 in 60 of the UK CF population [5]. Their
clinical presentation is similar to the white population
despite a different spectrum of cystic fibrosis transmem-
brane conductance regulator (CFTR) genotypes [5,6].
Pseudomonas aeruginosa (Pa) infection is a marker of
excess morbidity in CF and a single centre small study of
nine patients suggested that Asian CF patients have an
earlier acquisition of Pa infection, poorer lung function and1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
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1 Tel.: +44 1382 420115; fax: +44 1382 420101.lower weight centiles compared with age and gender
matched non-Asian controls [7]. Our objective was to test
this association between poor clinical outcomes and
ethnicity using the national database. Here, the clinical
status of UK Asian CF patients is compared with white CF
patients homozygous for the severe genotype [8] that
constitute around 50% of the UK CF population. The
hypothesis tested was that the clinical severity of CF in
Asians was comparable to the commonest form of CF in
the white population in the setting of modern treatment in
tertiary CF Centres. We show that FVC% predicted,
weight and BMI Z scores are lower in the Asian CF
patients compared with these white DF508/DF508 controls.
Because it remains controversial whether such outcomes
should be corrected for ethnicity, we conducted sub-
analyses with and without such adjustments. Our datas 4 (2005) 53–58ed by Elsevier B.V. All rights reserved.
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of CF in the Asian population.2. Methods
The operation of the UK Cystic Fibrosis Database or
UKCFD, which covers around 95% of specialist UK CF
Centres and smaller CF clinics, and its data verification
procedures have recently been described [9]. For a given
year, the UKCFD dactiveT patients are defined as the
subgroup of dregisteredT patients with basic biographical
data who have additional clinical data in the preceding 12
months [9]. Here, the UK CF registered population was
divided into white Caucasian and non-Caucasian popula-
tions. Within the predominantly ethnically mixed non-
Caucasian population, we identified an Asian CF population
consisting of all dactiveT Pakistani, Indian, Bangladeshi and
Asian/other patients [5].
At each CF Centre, an dactiveT Asian group was
compared with dactiveT white controls for clinical outcomes
in 2002 including forced expiratory volume in one second
and forced vital capacity percent predicted (FEV1 and
FVC% predicted), height, weight and body mass index
(BMI). dActiveT Asians were matched with up to five
controls. Due to differences in the spectrum of CFTR
mutations in the Asian population [5], cases and controls
could not be matched for genotype. Instead, we referenced
outcomes against the common and homozygous DF508
genotype. Each CF Centre control was an dactiveT white
patient matched for gender, age (F12 months) and chronic
Pa infection status (defined as three or more isolates in the
preceding 12 months). As CF-related diabetes (CFRD) is a
potentially confounding variable [10], patients taking either
insulin or oral hypoglycaemic agents were excluded from
both groups (this excluded 11 Asian patients, 6 male)
although the results remain unchanged if they were included
(data not shown).
The applicability of UK reference charts on lung function
and growth to children from ethnic minorities is contro-
versial [11–14]. There is the view that bethnic discountingQ
of FEV1% predicted values contributes nothing, as birth
weight, parental socio-economic status and maternal smok-
ing will also influence the accurate prediction and are not
accounted for in the calculation [15]. However, potentially
bcorrectiveQ adjustments exist for calculating FEV1 and
FVC% predicted according to ethnic origin. Therefore,
comparisons of lung function were performed in three ways.
Firstly, lung function was calculated using Polgar for
children and Cherniak for adults [16,17] and direct
comparisons of lung function were made between the Asian
group and controls directly (referred to as Polgar/Cherniak).
FEV1% predicted was calculated from the raw FEV1 data
using Polgar’s equation for children b18 years (male:
0.812*height in m2.77; female: 0.788*height in m2.73) and
Cherniak’s equation for adults N18 years (male: 0.04525*height in cm0.03509*age2.59946; female: 0.04071*
height in cm0.02147*age2.56958). FVC were similarly
calculated from the raw FVC data using Polgar’s equation
for children b18 years (male: 1.004*height in m2.72; female:
0.946*height in m2.61) and Cherniak’s equation for adults
N18 years (male: 0.06584*height in cm0.02954*age
5.12451; female: 0.05557*height in cm0.00793*age
4.89036). Secondly, the ethnic discounting of lung function
was applied according to the guidelines of the British
Thoracic Society and the Association of Respiratory
Technicians and Physiologists (referred to as BTS/ARTP),
which recommends that the predicted values of FEV1 and
FVC of Indian and Pakistani subjects should be multiplied
by a factor of 0.9 [18]. Lastly, our own formula incorporat-
ing the impact of nutrition on lung development were used
in a malnourished population in India as a reference base
[19] (referred to as Ong). The latter was applied to the Asian
and control groups equally, assuming malnourishment
would exist in both CF populations (predicted FEV1=
exp(2.83*ln(height in cm)13.43). There are no equivalent
formulae for FVC calculations.
With respect to height, another reason for using data
without specific adjustment for ethnicity is the secular trend
towards an increasing height in succeeding generations
especially where third generation immigrants and intermar-
riage has occurred permitting reference against national data
[14]. However, we also adjusted Asian data based on the
corrective factors published on a population of UK Pakistani
patients aged 4–14 years [13]. Adjustments to the height,
weight and BMI Z scores from the Asian CF group were
made as follows: male height +0.3, female height +0.4, male
weight +0.3, female weight +0.5, male BMI +0.4, female
BMI +0.5. The daily amount of pancreatic replacement
enzymes taken by pancreatic insufficient (PI) patients were
also compared.
Matching was allowed for in the analysis by assuming
the presence of additive random effects for each stratum
(group of case and matched controls) and a fixed effect
representing case-control difference. The SPSS mixed
model procedure was used to estimate the systematic effects
of gender and the case-control differences while allowing
for random variation at the level of the case-control stratum
as well as variation at the level of the individual subject.
Analyses were performed using Microsoft Access and Excel
97 (Microsoft Corporation, Redmond, Washington, USA),
SPSS for Windows version 11.5 (SPSS Inc., Chicago, IL,
USA) and graphical representations were prepared using
SigmaPlot (SigmaPlot for Windows version 4.01; SPSS
Inc., Chicago, IL, USA).3. Results
The UKCFD has 114 dregisteredT Asian CF patients (age
range 0.3 years to 34.3 years) from which we identified 50
dactiveT Asian CF patients (30 male) with corresponding
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Fig. 2. Mean differences in FVC% predicted between Asian patients and
controls for male (squares) and female (circles). Data based on 21 male
Asian CF patients with 52 matched controls, and 14 female Asian CF
patients with 29 matched control patients. The dotted line represents no
difference between the Asian and Caucasian groups. Filled and unfilled
symbols represent data unadjusted and adjusted for ethnicity, respectively.
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were excluded if they had no clinical data submitted in
2002, if no matching controls were identified or if they had
CFRD (36, 17 and 11 patients, respectively). The controls
consisted of 143 white Caucasians (92 male). The 50
dactiveT Asian subgroup (35 with lung function data) was
representative of the 114 Asian CF dregisteredT population
(62 with lung function data) with no significant differences
in the age at diagnosis ( p=0.40), height ( p=0.52), weight
( p=0.38) or BMI Z scores ( p=0.39), FEV1% predicted
( p=0.35), FVC% predicted ( p=0.46) or in the proportions
with chronic Pa infection ( p=0.28). The dactiveT Asians
included 34 Pakistani/Pakistani, 10 Indian/Indian, 3 Ban-
gladeshi/Bangladeshi, 2 Asian other/Asian other and 1
Pakistani/Bangladeshi. The UKCFD does not contain data
on parental consanguinity. The Asian chromosomes were
classified using the Welsh and Smith classification of CFTR
mutations: class I=8, class II=26, class III=0, class IV=0,
class V=3 and unknown=63, whereas the control group
patients all had class II mutations [20]. A third of the CFTR
mutations in the Asians remain undetectable by commonly
available screening methods. There were 14 Asian patients
(8 male) who carried at least one copy of the DF508
mutation, 12 of these were homozygous for DF508 (7 male).
Chronic Pa infection was recorded in 19 (38%) of the
Asians who were matched with chronic Pa infected
homozygous DF508 controls.
Lung function was available in 35 Asians (21 male) and
81 controls (52 male). Fig. 1 shows that the range of values
for mean FEV1% predicted in Asian males was between 3%
and 12% worse compared with controls. However, this trend
was of borderline significance dependent on the equation
used: Polgar/Cherniak ( p=0.072, mean difference 10.0
(95% confidence intervals (CI): 20.9, 0.9)), BTS/ARTP0
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Fig. 1. Mean differences in FEV1% predicted between Asian patients and
controls for male (squares) and female (circles). Data based on 21 male
Asian CF patients with 52 matched controls, and 14 female Asian CF
patients with 29 matched control patients. No difference between Asians
and controls is represented by the dotted line. FEV1% predicted
calculations: unadjusted (as per Polgar/Cherniak, filled symbols), ethnicity
adjustment (BTS/ARTP, unfilled symbols) and malnourishment adjustment
(Ong, grey symbols).( p=0.588, mean difference 2.9 (95% CI: 13.7, 7.8)) and
Ong methods ( p=0.061, mean difference 12.6 (95% CI:
25.8, 0.6)). In contrast, Asian females had between 9%
and 17% worse FEV1% predicted compared with controls
(Fig. 1), a deficit that remained significant using two of the
three bcorrectiveQ equations: Polgar/Cherniak ( p=0.025,
mean difference 14.9 (95% CI: 27.8, 2.0)), BTS/
ARTP ( p=0.127, mean difference 9.5 (95% CI: 21.9,
2.9)) and Ong methods ( p=0.024, mean difference 17.1
(95% CI: 31.8, 2.4)). Using the Polgar/Cherniak
method, Asian patients also had significantly worse
FVC% predicted compared to controls (Fig. 2); Asian males
compared with the controls calculated using the Polgar/
Cherniak ( p=0.001, mean difference 15.1 (95% CI:
24.0, 6.2)) and the BTS/ARTP methods ( p=0.083,
mean difference 8.0 (95% CI: 17.1, 1.1)); Asian females
compared with the controls calculated using the Polgar/
Cherniak method ( p=0.014, mean difference 15.2 (95%
CI: 27.1, 3.3)) and the BTS/ARTP method ( p=0.165,
mean difference 8.5 (95% CI: 20.8, 3.7)).
Asians had significantly lower unadjusted Z scores for
weight and BMI, but not height when directly compared
with white controls (Fig. 3). Mean differences in Z scores
for Asians compared with controls ( p values, 95% CI); male
weight 0.72 ( p=0.002, 1.18, 0.27), female weight
0.67 ( p=0.013, 1.20, 0.14), male BMI 0.74
( p=0.002, 1.19, 0.29) and female BMI 0.58
( p=0.008, 1.01, 0.16). Mean adjusted values for weight
and BMI were still lower than controls in Asian patients
after ethnicity adjustment, but these values were not
significantly different. There were no significant differ-
ences in levels of pancreatic enzyme replacement therapy
measured in lipase units/kg/day between Asian male or
female patients compared with controls. For the 27 Asian
PI male patients, mean lipase units/kg/day=9127 compared
with 8672 in the 91 PI male control patients ( p=0.57). For
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Fig. 3. Mean differences in height, weight and BMI Z scores between active
Asian patients and Caucasian homozygous DF508 controls, with and
without adjustment for ethnicity. Squares=males, circles=female. Data
based on 30 male Asian CF patients with 92 matched controls, and 20
female Asian CF patients with 51 matched controls. The dotted line
represents no difference between the Asian and Caucasian groups. Filled
and unfilled symbols represent data unadjusted and adjusted for ethnicity,
respectively.
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day=9322 compared with the 8605 in the 42 PI female
control patients ( p=0.48). There were no significant
differences in the proportions of male or female Asian
patients exceeding the recommended 10,000 lipase units/
kg/day [21,22] compared with the control patients (male
Asian patients 29.6%, pN0.05; female Asian patients
40.0%, pN0.05).4. Discussion
The interpretation of outcomes and the prediction of
morbidity in Asian CF are problematic due to the lack of
consensus over adjusting raw data for ethnicity when
comparing lung function and anthropometric data between
different ethnic groups. Therefore, we took the pragmatic
approach of comparing growth parameters, directly and
with ethnicity adjustment and compared lung function
using three separate formulae to adjust for ethnicity and
malnourishment. Ethnicity adjustments lack precision
associated with variations in height, weight, etc. of Asian
people from different regions and different socio-cultural
groups within the Indian subcontinent [6] and the trend
towards taller final height in succeeding generations of
immigrant populations [14]. We find that Asians with CF
had poorer FVC% predicted (but only poorer FEV1%
predicted in females), weight and BMI Z scores than the
homozygous DF508 white controls. There was no differ-
ence in height between Asian and control patients and,
although our study was not designed to explain this
observation, it could be a result of dietary influences,
similar levels of pancreatic insufficiency, or because the
null hypothesis is true. Although FEV1% predicted was notsignificantly worse in male Asians, the difference bordered
on significance and may be a reflection of the patient
numbers in our study. Larger patient numbers would be
achievable with an international CF database (which we
have proposed [23]), and better evidence could come from
prospective studies once neonatal screening is universal.
The majority of Asian CF patients live in England where
there are only a few hospitals with pilot newborn CF
screening programmes. It remains to be shown whether
these patients may differentially benefit from its introduc-
tion. The possible reasons for no difference between the
male Asians and white controls include a difference due to
ethnicity (cultural differences in the gender roles in Asian
society), nutritional factors or an influence such as
consanguinity producing a type II error. Therefore, we
suggest that the Asian CF phenotype is as severe as the
homozygous DF508 phenotype in white patients but may
be worse.
Epidemiological inferences based on racial categories are
criticised for overlooking confounding social, economic and
cultural variables [15,18]. The ethnicity of both parents of
CF patients is reported within the UKCFD but not
consanguinity, and the approach we report here is limited
by the lack of a detailed ethnic genealogy on each patient.
The fact that there are no significant differences in the age at
diagnosis or major symptoms at presentation between UK
white and Asian CF populations [5], despite the contrasting
spectrum of CFTR mutations, suggests that Asian origin is
not a barrier to early or appropriate diagnosis (nor is it a
barrier in US African–American CF patients [24]). Spenc-
er’s study in 1994 found that 5 out of 13 Asian CF children
had a delayed diagnosis as a direct result of their racial
origin [25]; however, our earlier work found no difference in
the age of diagnosis between 88 Asian patients and 5078
Caucasians using the national database [5]. Therefore, other
factors must be involved in the subsequent clinical course of
Asian CF patients in the UK.
There have been relatively few studies into Asian CF
patients because of the rarity of cases in any particular
region. Inclusion of ethnic minorities in research is
important and such research is ideally suited to a national
clinical database [26,27]. This enabled us to control for
important variables such as treatment differences between
CF Centres and clinics, chronic Pa infection, gender,
diabetic status and age in our study design. Our findings
agree with the study in Leeds that compared 9 UK-born
Asian CF patients with 18 non-Asian age and gender
matched controls [7]. Methodologically, that study used
standard reference charts for weight and height and did not
adjust for ethnicity, and applied the Polgar equation for lung
function to children as well as adults but had the advantage
of having detailed clinical histories and socio-economic
information on all their patients facilitating reporting on
social class and smoking status.
South Asians living in the UK have a higher prevalence
of coronary heart disease [28] though this has not been
J. McCormick et al. / Journal of Cystic Fibrosis 4 (2005) 53–58 57shown to be due to differences in medical care [29]. Socio-
cultural factors including diet, family income and language
barriers [7,19] and health care access and quality may all
contribute to the findings of our UK-wide study and can
have a major impact on outcomes especially survival in CF
[30–32]. CF is a complex disease to manage and insufficient
patient education, cultural acceptability of genetic condi-
tions and the impact of cultural beliefs on adherence to
treatment are challenging management issues [33]. It is
difficult to assess the contribution of the genotype to the
Asian CF phenotype, whilst no mutations are found in
approximately 40% of UK Asian patients [5] (a US study
reported 50% as unidentified or unknown [34]). However, it
would be useful if existing identified mutations seen in the
Asian population could be classified at a cellular level so
that genotype/phenotype correlations could be examined
[35]. This will become more important when new CFTR-
function specific therapies are introduced. Further work is
needed to elucidate the factors contributing to why Asian
CF patients have poorer lung function and our previous
work albeit in a different setting has suggested that diet
might be a factor in lung development [19]. More work is
needed to explore this association between ethnicity and
clinical outcome and we suggest that this vulnerable group
should merit particular attention. The factors leading to
these differences in lung function need to be explored but it
remains to be proven that early intervention will prevent
excess morbidity and mortality [36,37].Acknowledgements
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